We demonstrated that, in contrast to classical opioid receptors, ACKR3 doesn't result in classical G protein signaling and isn't modulated by the classical prescription or analgesic opioids, such as morphine, fentanyl, or buprenorphine, or by nonselective opioid antagonists like naloxone. Rather, we founded that LIH383, an ACKR3-selective subnanomolar competitor https://prussiab172wmc7.blogscribble.com/profile